What enlicitide is
Enlicitide is an oral PCSK9 inhibitor developed by Merck & Co. (known as MSD outside the U.S. and Canada). PCSK9 is a protein that causes the liver to destroy its LDL receptors, the receptors that pull LDL cholesterol out of the blood. Blocking PCSK9 leaves more receptors in place, so LDL levels fall. Until enlicitide, every approved PCSK9-targeting drug was an injection.
A target found through human genetics
PCSK9 is one of the clearest examples of a drug target discovered through genetics. In 2006, researchers reported that people carrying natural variants that disable PCSK9 had lifelong lower LDL cholesterol and substantially lower rates of coronary heart disease. Among Black participants, these variants were associated with 28% lower LDL and an 88% lower risk of coronary heart disease. That finding led directly to the injectable PCSK9 antibodies, and now to an oral drug. See What Are Genetic Mutations?
Regulatory status
The FDA approved Lipfendra (enlicitide), NDA 220848, on July 15, 2026, and announced it on July 17. According to the FDA, it is approved as an adjunct to diet and exercise to reduce LDL cholesterol in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia (HeFH). It received Priority Review and was reviewed under the Commissioner's National Priority Voucher pilot program. The label specifies a 20 mg tablet taken once daily on an empty stomach in the morning.
The approval is based on LDL lowering. The FDA's announcement does not claim that enlicitide reduces heart attacks or strokes.
Clinical evidence
CORALreef Lipids
This trial enrolled adults with a history of a major atherosclerotic cardiovascular event, or at risk of a first event, who were already receiving statins. Published in the New England Journal of Medicine in 2026:
| Measure | Enlicitide | Placebo |
|---|---|---|
| Participants (intention-to-treat) | 1,935 | 969 |
| Mean baseline LDL cholesterol | 96.1 mg/dL (all participants) | |
| Change in LDL cholesterol at week 24 | −57.1% | +3.0% |
| Between-group difference | −55.8 percentage points |
Non-HDL cholesterol, apolipoprotein B, and lipoprotein(a) also fell significantly more with enlicitide. The incidence of adverse events did not appear to differ between the groups.
CORALreef HeFH
In 303 adults with heterozygous familial hypercholesterolemia, a mean baseline LDL of 119 mg/dL, and all taking statins, LDL fell 58.2% with enlicitide at week 24, compared with a 2.6% rise with placebo. The between-group difference was −59.4 points at week 24 and −61.5 points at week 52 (JAMA, 2026).
CORALreef Outcomes
This is the trial that will determine whether enlicitide reduces cardiovascular events. ClinicalTrials.gov lists an estimated 14,550 participants and an estimated primary completion in November 2029.
Scientific perspective
LDL cholesterol is a validated surrogate endpoint. The Lipfendra label makes the reasoning explicit: it notes that cardiovascular outcomes trials have shown that reducing LDL lowers the risk of major adverse cardiovascular events in adults treated with statins or with monoclonal antibody PCSK9 inhibitors added to statins. In other words, the approval relies on outcomes evidence from other LDL-lowering drugs, including drugs acting on the same target. Surrogates have misled before, however (see What Is a Primary Clinical Trial Endpoint?), so the outcomes trial still matters for confirming the benefit and assessing long-term safety.
Development perspective
- Approved use: LDL lowering in adults with hypercholesterolemia, including HeFH. No benchmark is shown because the program is approved.
- Next milestone: CORALreef Outcomes, estimated primary completion November 2029 (registry). A positive result could support a cardiovascular risk-reduction claim.
- Further programs: pediatric familial hypercholesterolemia (Phase 2/3, recruiting) and a Phase 2 combination study with another Merck investigational drug, MK-7262 (registry).
Competitive context
Enlicitide joins statins, ezetimibe, bempedoic acid, injectable PCSK9 antibodies, and the PCSK9 siRNA inclisiran. It is the first PCSK9-targeting option in pill form. A once-daily oral PCSK9 inhibitor competes on convenience, while the injectables offer dosing every two weeks to every six months. Oral CETP inhibition with obicetrapib, which is approved in the EU but not the U.S., is another oral LDL-lowering approach in development.
Development timeline
- Mar 10, 2022Phase 2 trial of MK-0616 begins (381 participants). Registry
- Aug 10, 2023CORALreef Lipids Phase 3 trial begins. Registry
- Oct 9, 2023CORALreef Outcomes cardiovascular outcomes trial begins. Registry
- Jan 13, 2026CORALreef HeFH published: LDL −58.2% versus +2.6% with placebo at week 24 in heterozygous familial hypercholesterolemia. Peer-reviewed
- Feb 5, 2026CORALreef Lipids published: LDL −57.1% versus +3.0% with placebo at week 24. Peer-reviewed
- Jul 15, 2026FDA approves Lipfendra (enlicitide), NDA 220848, the first oral PCSK9 inhibitor. Regulator
What could change the outlook
- The CORALreef Outcomes result, which will show whether enlicitide reduces major cardiovascular events. The registry estimates primary completion in November 2029.
- Real-world adherence, since the pill is taken once daily on an empty stomach in the morning, according to the label.
- Regulatory decisions outside the U.S.
- Pediatric results from the Phase 2/3 trial in children with familial hypercholesterolemia (registry).
Latest company disclosures
Company press releases (SEC filings and PR Newswire) that mention Enlicitide. Company-reported, not independently verified.
- Quarterly reportCompany-reportedAug 4, 2026
Merck & Co., Inc., Rahway, N.J., USA Announces Second-Quarter 2026 Financial Results; Highlights Key Regulatory and Clinical Milestones Across Broad, Diverse Pipeline
“The FDA approval of LIPFENDRA is an exciting moment for our company and for patients, marking the latest milestone in our nearly 70-year legacy in cardiovascular disease.